Role of Methylcobalamine in Type 2 Diabetes Mellitus patients
Not Applicable
- Conditions
- Health Condition 1: E114- Type 2 diabetes mellitus with neurological complicationsHealth Condition 2: E114- Type 2 diabetes mellitus with neurological complications
- Registration Number
- CTRI/2020/06/026074
- Lead Sponsor
- self sponsored intramural
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All known diabetics more than or equal to five years
Exclusion Criteria
1.Patients already on methyl-cobalamine treatment
2.Patients who were severely ill, mentally challenged or unable to communicate
3.Patients with chronic lower back pain, neurological history and clinical examination suggestive of myelopathies
4.Pregnant women and patients taking medication known to impair nerve function.
5.Patients not willing to participate in study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Decrease in the severity or not increase in the severity of diabetic peripheral neuropathyTimepoint: after 6 month of therapy
- Secondary Outcome Measures
Name Time Method impact on nephropathy and retinopathyTimepoint: after 6 month of tgerapy